Journal of Oncology Pharmacy Practice

Papers
(The H4-Index of Journal of Oncology Pharmacy Practice is 15. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)
ArticleCitations
Afatinib for the treatment of EGFR mutation-positive NSCLC: A review of clinical findings62
Fibroblast growth factor receptor (FGFR) inhibitors: A review of a novel therapeutic class40
Outcome of COVID-19 in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors29
A drug repositioning success: The repositioned therapeutic applications and mechanisms of action of thalidomide27
Cancer patient experience of telephone clinics implemented in light of COVID-1925
Oral silymarin formulation efficacy in management of AC-T protocol induced hepatotoxicity in breast cancer patients: A randomized, triple blind, placebo-controlled clinical trial19
Clinical course of COVID-19 infection in elderly patient with melanoma on nivolumab19
Factors affecting health-related quality of life among prostate cancer patients: A systematic review19
Comparative effects of fluconazole, posaconazole, and isavuconazole upon tacrolimus and cyclosporine serum concentrations16
Cisplatin-induced nephrotoxicity in children: what is the best protective strategy?16
Tagraxofusp followed by combined azacitidine and venetoclax in blastic plasmacytoid dendritic cell neoplasm: A case report and literature review16
ISOPP Standards for the Safe Handling of Cytotoxics16
Cryotherapy for the prevention of chemotherapy-induced peripheral neuropathy: A systematic review15
Spine eburnation in a metastatic lung cancer patient treated with immunotherapy and radiotherapy. The first case report of bystander effect on bone15
Tofacitinib for treatment in immune-mediated myocarditis: The first reported cases15
Multiple autoimmune side effects of immune checkpoint inhibitors in a patient with metastatic melanoma receiving pembrolizumab15
0.096935033798218